首页 > 最新文献

Therapeutic Apheresis and Dialysis最新文献

英文 中文
Retrospective observational study of changes in serum cytokines and adiponectin with continuous plasma exchange with dialysis therapy for severe COVID-19. 持续血浆置换透析治疗重症新冠肺炎患者血清细胞因子和脂联素变化的回顾性观察研究。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-31 DOI: 10.1111/1744-9987.14054
Yuya Suzuki, Hajime Nakae, Kasumi Satoh, Nobuhisa Hirasawa, Komei Kameyama, Yasuhito Irie, Toshiharu Kitamura, Tasuku Nara, Kyohei Maeno, Kenji Yoshida, Manabu Okuyama

Introduction: Coronavirus disease 2019 (COVID-19) is associated with a marked increase in the inflammatory cytokines, IL-6 and IL-18. Blood purification therapy aimed at controlling cytokines is one treatment option; however, evidence of its effectiveness is needed. Plasma exchange with dialysis (PED) is a blood purification method involving selective plasma exchange with dialysate flowing through the outer hollow fiber of the plasma separator. In this retrospective study, we investigated the efficacy of continuous PED (cPED) over 48 h in five patients with severe COVID-19.

Methods: We assessed changes in IL-6 and IL-18, as well as adiponectin (APN).

Results: There were no significant differences in changes in IL-6 and IL-18, but there was a marked improvement in cases with abnormally high IL-6 and IL-18 levels at baseline. APN, which inhibits inflammatory cytokines, was significantly elevated post-cPED.

Conclusion: Our results suggest that cPED therapy is an effective treatment for COVID-19.

简介:2019冠状病毒病(新冠肺炎)与炎性细胞因子IL-6和IL-18的显著增加有关。旨在控制细胞因子的血液净化疗法是一种治疗选择;然而,还需要证明其有效性的证据。透析血浆交换(PED)是一种血液净化方法,涉及与流经血浆分离器的外部中空纤维的透析液进行选择性血浆交换。在这项回顾性研究中,我们调查了连续PED(cPED)在48岁以上的疗效 方法:我们评估了IL-6、IL-18以及脂联素(APN)的变化。结果:IL-6和IL-18的变化没有显著差异,但在基线时IL-6和IL-118水平异常高的病例中有显著改善。抑制炎性细胞因子的APN在cPED后显著升高。结论:cPED治疗新冠肺炎是一种有效的治疗方法。
{"title":"Retrospective observational study of changes in serum cytokines and adiponectin with continuous plasma exchange with dialysis therapy for severe COVID-19.","authors":"Yuya Suzuki,&nbsp;Hajime Nakae,&nbsp;Kasumi Satoh,&nbsp;Nobuhisa Hirasawa,&nbsp;Komei Kameyama,&nbsp;Yasuhito Irie,&nbsp;Toshiharu Kitamura,&nbsp;Tasuku Nara,&nbsp;Kyohei Maeno,&nbsp;Kenji Yoshida,&nbsp;Manabu Okuyama","doi":"10.1111/1744-9987.14054","DOIUrl":"10.1111/1744-9987.14054","url":null,"abstract":"<p><strong>Introduction: </strong>Coronavirus disease 2019 (COVID-19) is associated with a marked increase in the inflammatory cytokines, IL-6 and IL-18. Blood purification therapy aimed at controlling cytokines is one treatment option; however, evidence of its effectiveness is needed. Plasma exchange with dialysis (PED) is a blood purification method involving selective plasma exchange with dialysate flowing through the outer hollow fiber of the plasma separator. In this retrospective study, we investigated the efficacy of continuous PED (cPED) over 48 h in five patients with severe COVID-19.</p><p><strong>Methods: </strong>We assessed changes in IL-6 and IL-18, as well as adiponectin (APN).</p><p><strong>Results: </strong>There were no significant differences in changes in IL-6 and IL-18, but there was a marked improvement in cases with abnormally high IL-6 and IL-18 levels at baseline. APN, which inhibits inflammatory cytokines, was significantly elevated post-cPED.</p><p><strong>Conclusion: </strong>Our results suggest that cPED therapy is an effective treatment for COVID-19.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10124519","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effects of sodium thiosulfate on serum calcification factors in patients undergoing maintenance hemodialysis. 硫代硫酸钠对维持性血液透析患者血清钙化因子的影响。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-07-09 DOI: 10.1111/1744-9987.14029
Pan Liu, Xiang Xu, YuFu Wang, XiaoNa Long, XunJia Li, HongYing Peng

Objective: To investigate the effect of sodium thiosulfate (STS) on serum calcification factors in patients undergoing maintenance hemodialysis.

Methods: Forty-four Patients were randomly divided into control group (n = 22) and observation group (n = 22) by envelope method (block 4 randomization). The control group received routine treatment while observation group was treated with STS on the basis of routine treatment. The biochemical indicators, including BUN, UA, SCr, Ca2+ , P3- , calcium-phosphorus product, PTH, hs-CRP, TG, TC, HDL, LDL, and serum calcification factor MGP, FA, FGF-23, and OPG levels were compared before and after treatment.

Results: Control group had no statistically significant difference in the levels of vascular calcification factors MGP, FA, FGF-23, and OPG before and after treatment (p > 0.05). Whereas observation group had higher levels of MGP and FA, and lower levels of FGF-23 and OPG after treatment than before treatment (p < 0.05). The levels of MGP and FA in observation group were higher than those in control group, and FGF-23 and OPG were lower than those in control group (p < 0.05).

Conclusion: It is speculated that sodium thiosulfate can alleviate the progression of vascular calcification by changing the levels of calcification factors.

目的:探讨硫代硫酸钠(STS)对维持性血液透析患者血清钙化因子的影响。方法:将44例患者随机分为对照组(n = 22)和观察组(n = 22)(块4随机化)。对照组采用常规治疗,观察组在常规治疗的基础上采用STS治疗。比较治疗前后的生化指标,包括BUN、UA、SCr、Ca2+、P3-、钙磷产物、PTH、hs-CRP、TG、TC、HDL、LDL以及血清钙化因子MGP、FA、FGF-23和OPG水平。结果:对照组治疗前后血管钙化因子MGP、FA、FGF-23、OPG水平差异无统计学意义(p > 观察组治疗后MGP和FA水平高于治疗前,FGF-23和OPG水平低于治疗前(p 结论:硫代硫酸钠可以通过改变钙化因子的水平来减轻血管钙化的进展。
{"title":"Effects of sodium thiosulfate on serum calcification factors in patients undergoing maintenance hemodialysis.","authors":"Pan Liu,&nbsp;Xiang Xu,&nbsp;YuFu Wang,&nbsp;XiaoNa Long,&nbsp;XunJia Li,&nbsp;HongYing Peng","doi":"10.1111/1744-9987.14029","DOIUrl":"10.1111/1744-9987.14029","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of sodium thiosulfate (STS) on serum calcification factors in patients undergoing maintenance hemodialysis.</p><p><strong>Methods: </strong>Forty-four Patients were randomly divided into control group (n = 22) and observation group (n = 22) by envelope method (block 4 randomization). The control group received routine treatment while observation group was treated with STS on the basis of routine treatment. The biochemical indicators, including BUN, UA, SCr, Ca<sup>2+</sup> , P<sup>3-</sup> , calcium-phosphorus product, PTH, hs-CRP, TG, TC, HDL, LDL, and serum calcification factor MGP, FA, FGF-23, and OPG levels were compared before and after treatment.</p><p><strong>Results: </strong>Control group had no statistically significant difference in the levels of vascular calcification factors MGP, FA, FGF-23, and OPG before and after treatment (p > 0.05). Whereas observation group had higher levels of MGP and FA, and lower levels of FGF-23 and OPG after treatment than before treatment (p < 0.05). The levels of MGP and FA in observation group were higher than those in control group, and FGF-23 and OPG were lower than those in control group (p < 0.05).</p><p><strong>Conclusion: </strong>It is speculated that sodium thiosulfate can alleviate the progression of vascular calcification by changing the levels of calcification factors.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9761086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effects of N-acetyl-L-tryptophan on desorption of the protein-bound uremic toxin indoxyl sulfate and effects on uremic sarcopenia. N-乙酰-L-色氨酸对蛋白结合的尿毒症毒素硫酸吲哚酚解吸的影响以及对尿毒症少肌症的影响。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-19 DOI: 10.1111/1744-9987.14047
Atsushi Ohashi, Masashi Nakatani, Hideo Hori, Shigeru Nakai, Kunihiro Tsuchida, Midori Hasegawa, Naotake Tsuboi

Introduction: Indoxyl sulfate (IS) is a protein-bound uremic toxin that causes uremic sarcopenia. IS has poor dialysis clearance; however, the addition of a binding competitor improves its removal efficiency.

Methods: Dialysis experiments were performed using N-acetyl-l-tryptophan (L-NAT) instead of l-tryptophan (Trp) using pooled sera obtained from dialysis patients. The molecular structures of L-NAT and Trp were similar to that of IS. Therefore, we examined whether Trp and L-NAT were involved in muscle atrophy in the same manner as IS by performing culture experiments using a human myotube cell line.

Results: The removal efficiency of L-NAT was the same as that of Trp. However, L-NAT concentrations in the pooled sera increased at the end of the experiment. Trp (1 mM) decreased the area of human myocytes, similar to IS, whereas L-NAT did not.

Conclusion: L-NAT is a binding competitor with the ability to remove protein-bound IS while preventing sarcopenia.

引言:硫酸吲哚酚(IS)是一种与蛋白质结合的尿毒症毒素,可导致尿毒症少肌症。IS透析清除率低;然而,添加结合竞争对手提高了其去除效率。方法:使用从透析患者获得的混合血清,使用N-乙酰-l-色氨酸(l-NAT)代替l-色氨酸进行透析实验。L-NAT和Trp的分子结构与IS相似。因此,我们通过使用人肌管细胞系进行培养实验来检测Trp和L-NAT是否以与IS相同的方式参与肌肉萎缩。结果:L-NAT的去除效率与Trp的去除效率相同,但在实验结束时,合并血清中的L-NAT浓度增加。Trp(1 mM)降低了人肌细胞的面积,类似于IS,而L-NAT没有。结论:L-NAT是一种结合竞争对手,能够去除蛋白结合的is,同时预防少肌症。
{"title":"Effects of N-acetyl-L-tryptophan on desorption of the protein-bound uremic toxin indoxyl sulfate and effects on uremic sarcopenia.","authors":"Atsushi Ohashi,&nbsp;Masashi Nakatani,&nbsp;Hideo Hori,&nbsp;Shigeru Nakai,&nbsp;Kunihiro Tsuchida,&nbsp;Midori Hasegawa,&nbsp;Naotake Tsuboi","doi":"10.1111/1744-9987.14047","DOIUrl":"10.1111/1744-9987.14047","url":null,"abstract":"<p><strong>Introduction: </strong>Indoxyl sulfate (IS) is a protein-bound uremic toxin that causes uremic sarcopenia. IS has poor dialysis clearance; however, the addition of a binding competitor improves its removal efficiency.</p><p><strong>Methods: </strong>Dialysis experiments were performed using N-acetyl-l-tryptophan (L-NAT) instead of l-tryptophan (Trp) using pooled sera obtained from dialysis patients. The molecular structures of L-NAT and Trp were similar to that of IS. Therefore, we examined whether Trp and L-NAT were involved in muscle atrophy in the same manner as IS by performing culture experiments using a human myotube cell line.</p><p><strong>Results: </strong>The removal efficiency of L-NAT was the same as that of Trp. However, L-NAT concentrations in the pooled sera increased at the end of the experiment. Trp (1 mM) decreased the area of human myocytes, similar to IS, whereas L-NAT did not.</p><p><strong>Conclusion: </strong>L-NAT is a binding competitor with the ability to remove protein-bound IS while preventing sarcopenia.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10029034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experience with pre-diluted plasma exchange therapy for hyperviscosity syndrome. 预稀释血浆置换治疗高粘滞综合征的经验。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-21 DOI: 10.1111/1744-9987.14053
Shigeyuki Igarashi, Yasutaka Kamikawa, Syuji Ono, Gakuya Maekawa, Hiroyuki Kishigami, Kazuki Kawamura, Takumi Oonogi, Toshihiko Nagano

Introduction: Plasma exchange therapy (PE) is useful for patients with primary macroglobulinemia and multiple myeloma who present with hyperviscosity syndrome. However, hyperviscous blood may coagulate in the circuit during treatment, and in that case necessitate discontinuation of the treatment. This time, we report that we were able to prevent coagulation in the circuit by adding some ideas during the membrane separation method.

Methods: Physiological saline is injected in front of the plasma separation membrane to pre-dilute the blood, followed by filtration through the plasma separation membrane.

Results: As a result of pre-diluting with physiological saline to reduce the viscosity entering the separation membrane, it was possible to process the planned target amount.

Conclusion: In patients with hyperviscosity syndrome who showed intracircuit coagulation during plasma exchange therapy, devising a predilution method should be considered as one of the ways to continue treatment.

引言:血浆置换疗法(PE)适用于原发性巨球蛋白血症和多发性骨髓瘤伴高粘滞综合征的患者。然而,在治疗过程中,高粘度血液可能会在回路中凝结,在这种情况下,需要停止治疗。这一次,我们报告说,我们能够通过在膜分离方法中添加一些想法来防止回路中的凝结。方法:在血浆分离膜前注入生理盐水预稀释血液,然后通过血浆分离膜过滤。结果:由于用生理盐水预稀释以降低进入分离膜的粘度,因此可以处理计划的目标量。结论:对于在血浆置换治疗过程中出现回路内凝血的高粘度综合征患者,应考虑设计预溶解方法作为继续治疗的方法之一。
{"title":"Experience with pre-diluted plasma exchange therapy for hyperviscosity syndrome.","authors":"Shigeyuki Igarashi,&nbsp;Yasutaka Kamikawa,&nbsp;Syuji Ono,&nbsp;Gakuya Maekawa,&nbsp;Hiroyuki Kishigami,&nbsp;Kazuki Kawamura,&nbsp;Takumi Oonogi,&nbsp;Toshihiko Nagano","doi":"10.1111/1744-9987.14053","DOIUrl":"10.1111/1744-9987.14053","url":null,"abstract":"<p><strong>Introduction: </strong>Plasma exchange therapy (PE) is useful for patients with primary macroglobulinemia and multiple myeloma who present with hyperviscosity syndrome. However, hyperviscous blood may coagulate in the circuit during treatment, and in that case necessitate discontinuation of the treatment. This time, we report that we were able to prevent coagulation in the circuit by adding some ideas during the membrane separation method.</p><p><strong>Methods: </strong>Physiological saline is injected in front of the plasma separation membrane to pre-dilute the blood, followed by filtration through the plasma separation membrane.</p><p><strong>Results: </strong>As a result of pre-diluting with physiological saline to reduce the viscosity entering the separation membrane, it was possible to process the planned target amount.</p><p><strong>Conclusion: </strong>In patients with hyperviscosity syndrome who showed intracircuit coagulation during plasma exchange therapy, devising a predilution method should be considered as one of the ways to continue treatment.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10040026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is photopheresis? Role of extracorporeal photopheresis in the treatment of GvHD and its practice in Sweden. 什么是照相术?体外光疗法在GvHD治疗中的作用及其在瑞典的实践。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-09-10 DOI: 10.1111/1744-9987.14051
Yoshimi Fukumaki Karlsson, Gösta Berlin
{"title":"What is photopheresis? Role of extracorporeal photopheresis in the treatment of GvHD and its practice in Sweden.","authors":"Yoshimi Fukumaki Karlsson, Gösta Berlin","doi":"10.1111/1744-9987.14051","DOIUrl":"10.1111/1744-9987.14051","url":null,"abstract":"","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10203113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Determination of anxiety, depression, avoidance and obsessions experienced by hemodialysis patients during the COVID-19. 新冠肺炎期间血液透析患者经历的焦虑、抑郁、回避和强迫的测定。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-06-29 DOI: 10.1111/1744-9987.14031
Nazlı Koşunalp, Mehtap Kavurmaci

Introduction: The purpose of this study was to ascertain the levels of anxiety, despair, avoidance, and obsessions that hemodialysis patients dealt with during the pandemic.

Methods: The study was conducted with 139 hemodialysis patients. Research data "Coronavirus Anxiety Scale (CAS)," "Hospital Anxiety and Depression Scale (HAD)," "COVID-19 Avoidance Scale" (AA-COVID-19) and "Coronavirus Obsession Scale (OCS)." The data obtained from the research were analyzed using the SPSS 21 package program.

Results: The average score of the patients on the CAS scale was 0.73 ± 1.17, on the HAD-A scale was 5.94 ± 3.67, and on the HAD-D scale was 7.06 ± 3.89. The COVID-19 outbreak has consequently had a severe impact on hemodialysis patients' mental health.

Conclusion: Covid 19 epidemic, the health sector failed to protect the mental health of patients. However, new epidemics and disasters await the world in the future. In these results show that new strategies need to be developed.

引言:本研究的目的是确定血液透析患者在疫情期间的焦虑、绝望、回避和痴迷程度。方法:对139例血液透析患者进行研究。研究数据“冠状病毒焦虑量表(CAS)”、“医院焦虑和抑郁量表(HAD)”、《新冠肺炎回避量表》(AA-CVID-19)和《冠状病毒困扰量表(OCS)》。结果:患者在CAS量表上的平均得分为0.73 ± 1.17,HAD-A评分为5.94 ± 3.67,HAD-D量表为7.06 ± 3.89.新冠肺炎疫情因此对血液透析患者的心理健康产生了严重影响。结论:新冠肺炎疫情19日,卫生部门未能保护患者的心理健康。然而,新的流行病和灾难在未来等待着世界。这些结果表明,需要制定新的战略。
{"title":"Determination of anxiety, depression, avoidance and obsessions experienced by hemodialysis patients during the COVID-19.","authors":"Nazlı Koşunalp,&nbsp;Mehtap Kavurmaci","doi":"10.1111/1744-9987.14031","DOIUrl":"10.1111/1744-9987.14031","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to ascertain the levels of anxiety, despair, avoidance, and obsessions that hemodialysis patients dealt with during the pandemic.</p><p><strong>Methods: </strong>The study was conducted with 139 hemodialysis patients. Research data \"Coronavirus Anxiety Scale (CAS),\" \"Hospital Anxiety and Depression Scale (HAD),\" \"COVID-19 Avoidance Scale\" (AA-COVID-19) and \"Coronavirus Obsession Scale (OCS).\" The data obtained from the research were analyzed using the SPSS 21 package program.</p><p><strong>Results: </strong>The average score of the patients on the CAS scale was 0.73 ± 1.17, on the HAD-A scale was 5.94 ± 3.67, and on the HAD-D scale was 7.06 ± 3.89. The COVID-19 outbreak has consequently had a severe impact on hemodialysis patients' mental health.</p><p><strong>Conclusion: </strong>Covid 19 epidemic, the health sector failed to protect the mental health of patients. However, new epidemics and disasters await the world in the future. In these results show that new strategies need to be developed.</p>","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10055506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 43rd Annual Meeting of the Japanese Society for Apheresis. 第43届日本单采术学会年会。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-12-01 Epub Date: 2023-08-17 DOI: 10.1111/1744-9987.14055
Takashi Wada
{"title":"The 43rd Annual Meeting of the Japanese Society for Apheresis.","authors":"Takashi Wada","doi":"10.1111/1744-9987.14055","DOIUrl":"10.1111/1744-9987.14055","url":null,"abstract":"","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10396727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic Apheresis and Dialysis Forthcoming Events December 2023 治疗性采血和透析即将举行的活动2023年12月
4区 医学 Q3 Medicine Pub Date : 2023-11-02 DOI: 10.1111/1744-9987.13882
Therapeutic Apheresis and DialysisVolume 27, Issue 6 p. 1130-1130 FORTHCOMING EVENTS Therapeutic Apheresis and Dialysis Forthcoming Events December 2023 First published: 02 November 2023 https://doi.org/10.1111/1744-9987.13882Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume27, Issue6December 2023Pages 1130-1130 RelatedInformation
治疗单采和透析第27卷第6期1130-1130即将发生的事件治疗单采和透析即将发生的事件2023年12月首次出版:2023年11月2日https://doi.org/10.1111/1744-9987.13882Read全文taboutpdf ToolsRequest permissionExport citation添加到favoritesTrack citation ShareShare给予accessShare全文accessShare全文accessShare全文accessShare全文accessShare请查看我们的使用条款和条件,并勾选下面的复选框以分享文章的全文版本。我已经阅读并接受了Wiley在线图书馆使用共享链接的条款和条件,请使用下面的链接与您的朋友和同事分享本文的全文版本。学习更多的知识。复制URL共享链接共享一个emailfacebooktwitterlinkedinreddit微信本文无摘要vol . 27, Issue6December 2023Pages 1130-1130
{"title":"<i>Therapeutic Apheresis and Dialysis</i> Forthcoming Events December 2023","authors":"","doi":"10.1111/1744-9987.13882","DOIUrl":"https://doi.org/10.1111/1744-9987.13882","url":null,"abstract":"Therapeutic Apheresis and DialysisVolume 27, Issue 6 p. 1130-1130 FORTHCOMING EVENTS Therapeutic Apheresis and Dialysis Forthcoming Events December 2023 First published: 02 November 2023 https://doi.org/10.1111/1744-9987.13882Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. Volume27, Issue6December 2023Pages 1130-1130 RelatedInformation","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135973490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corporate Members. 公司成员。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-10-01 DOI: 10.1111/1744-9987.13880
Asahi Kasei Medical Co., Ltd. (Tokyo, Japan) is a world leader in research, development, and production of devices and systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It serves the global market with dialysis products and therapeutic apheresis devices, such as membrane type plasma separators, plasma component separators, and immunoadsorption columns. Asahi Kasei Medical’s core competence is in blood related polymer technologies, materials technologies, and blood analysis technologies. The Research and Development Division is developing next-generation products based in these technologies for fields ranging from extracorporeal therapy to organ function diagnosis and artificial organs. Now, as always, Asahi Kasei Medical is dedicated to serving and advancing medical therapy for the preservation and enhancement of human life. Website: http://www.asahikasei-medical.com
{"title":"Corporate Members.","authors":"","doi":"10.1111/1744-9987.13880","DOIUrl":"10.1111/1744-9987.13880","url":null,"abstract":"Asahi Kasei Medical Co., Ltd. (Tokyo, Japan) is a world leader in research, development, and production of devices and systems for blood treatment and purification based on advanced membrane separation and adsorption technologies. It serves the global market with dialysis products and therapeutic apheresis devices, such as membrane type plasma separators, plasma component separators, and immunoadsorption columns. Asahi Kasei Medical’s core competence is in blood related polymer technologies, materials technologies, and blood analysis technologies. The Research and Development Division is developing next-generation products based in these technologies for fields ranging from extracorporeal therapy to organ function diagnosis and artificial organs. Now, as always, Asahi Kasei Medical is dedicated to serving and advancing medical therapy for the preservation and enhancement of human life. Website: http://www.asahikasei-medical.com","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10150788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inclisiran and lipoprotein apheresis in statin intolerance heterozygous FH patients: A case series. 他汀类药物不耐受杂合子FH患者的Incisiran和脂蛋白单采:一个病例系列。
IF 1.9 4区 医学 Q3 Medicine Pub Date : 2023-10-01 Epub Date: 2023-06-14 DOI: 10.1111/1744-9987.14025
Beatrice Dal Pino, Federico Bigazzi, Francesco Sbrana
Dear Editor, In Familial Hypercholesterolemia (FH), statins treatment is the first choice to lower LDL cholesterol and to reduce cardiovascular morbidity and mortality, however, up to 10% of patients treated with statins report intolerance [1]. Monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (mAb PCSK9i) could be administered to lower LDL cholesterol in patients with muscle-related adverse events, but intolerance to mAb PCSK9i has also been described [2]. Within this context, Lipoprotein Apheresis (LA) still holds a valuable role, even in the new era of Lipid-Lowering Therapy (LLT) [2]. Inclisiran is a novel small interfering RNA-based drug (siRNA) anti-PCSK9 play a role in patients when optimal LDL-C cannot be achieved by statins and/or mAb PCSK9i [3]. We enrolled 5 patients in chronic LA (mean age 64 ± 8 years, female 60%) affected by heterozygous FH and AtheroSclerotic CardioVascular Disease (ASCVD), with history of statin intolerance and mAb PCSK9i adverse events (flue like syndrome in 3/5 patients, severe CPK increase in 1/5 patient and low therapeutic compliance in 1/5 patient). These patients, after the discontinuation of mAb PCSK9i, were assigned to inclisiran therapy (dosing schedule: 284 mg s.c. injection of at 0–90–180 days and every 6 months thereafter) and followed up for 3 months. The LA treatment was performed at bi-weekly interval by dextran-sulfate (Liposorber-LA systems; Kaneka, Osaka, Japan; 3/5 patients) or heparin-induced LDL precipitation apheresis (HELP, Plasmat Futura; B. Braun, Melsungen, Germany; 2/5 patients). After 3 months of therapy, a significant decrease in total cholesterol ( 19%), LDL cholesterol ( 27%), Apo B lipoprotein ( 24%) and triglycerides ( 13%) levels was observed without significant modification in other parameters (see Table S1). During the study period, the clinical response between inclisiran and mAb PCSK9i showed no difference (see Figure 1). One patient who achieved the recommended therapeutic target for LDL cholesterol and Lp(a) levels (respectively below 55 and 60 mg/dL, as indicated by international guidelines) discontinued LA. Adverse events were reported in 2/5 (40%) of patients: one referred transient episodes of mild difficulty to maintain concentration after 2 weeks of drug administration, another patient presented a cutaneous herpes zoster infection. No injection-site reaction was reported. In contrast to mAb PCSK9i, inclisiran inactivates PCSK9 by inhibition of its hepatic synthesis. The safety, tolerability, and efficacy of inclisiran have been studied within the ORION clinical development program who demonstrated a sustained PCSK9 suppression of about 80% and time-adjusted LDL-C reduction of approximately 50% from baseline. Furthermore, the safety profile of inclisiran was found to be comparable to that of mAb PCSK9i and the most commonly reported adverse effect was a mild-to-moderate transient injection site reaction [3]. It provides a therapeutic
{"title":"Inclisiran and lipoprotein apheresis in statin intolerance heterozygous FH patients: A case series.","authors":"Beatrice Dal Pino,&nbsp;Federico Bigazzi,&nbsp;Francesco Sbrana","doi":"10.1111/1744-9987.14025","DOIUrl":"10.1111/1744-9987.14025","url":null,"abstract":"Dear Editor, In Familial Hypercholesterolemia (FH), statins treatment is the first choice to lower LDL cholesterol and to reduce cardiovascular morbidity and mortality, however, up to 10% of patients treated with statins report intolerance [1]. Monoclonal antibodies against Proprotein Convertase Subtilisin/Kexin type 9 inhibitors (mAb PCSK9i) could be administered to lower LDL cholesterol in patients with muscle-related adverse events, but intolerance to mAb PCSK9i has also been described [2]. Within this context, Lipoprotein Apheresis (LA) still holds a valuable role, even in the new era of Lipid-Lowering Therapy (LLT) [2]. Inclisiran is a novel small interfering RNA-based drug (siRNA) anti-PCSK9 play a role in patients when optimal LDL-C cannot be achieved by statins and/or mAb PCSK9i [3]. We enrolled 5 patients in chronic LA (mean age 64 ± 8 years, female 60%) affected by heterozygous FH and AtheroSclerotic CardioVascular Disease (ASCVD), with history of statin intolerance and mAb PCSK9i adverse events (flue like syndrome in 3/5 patients, severe CPK increase in 1/5 patient and low therapeutic compliance in 1/5 patient). These patients, after the discontinuation of mAb PCSK9i, were assigned to inclisiran therapy (dosing schedule: 284 mg s.c. injection of at 0–90–180 days and every 6 months thereafter) and followed up for 3 months. The LA treatment was performed at bi-weekly interval by dextran-sulfate (Liposorber-LA systems; Kaneka, Osaka, Japan; 3/5 patients) or heparin-induced LDL precipitation apheresis (HELP, Plasmat Futura; B. Braun, Melsungen, Germany; 2/5 patients). After 3 months of therapy, a significant decrease in total cholesterol ( 19%), LDL cholesterol ( 27%), Apo B lipoprotein ( 24%) and triglycerides ( 13%) levels was observed without significant modification in other parameters (see Table S1). During the study period, the clinical response between inclisiran and mAb PCSK9i showed no difference (see Figure 1). One patient who achieved the recommended therapeutic target for LDL cholesterol and Lp(a) levels (respectively below 55 and 60 mg/dL, as indicated by international guidelines) discontinued LA. Adverse events were reported in 2/5 (40%) of patients: one referred transient episodes of mild difficulty to maintain concentration after 2 weeks of drug administration, another patient presented a cutaneous herpes zoster infection. No injection-site reaction was reported. In contrast to mAb PCSK9i, inclisiran inactivates PCSK9 by inhibition of its hepatic synthesis. The safety, tolerability, and efficacy of inclisiran have been studied within the ORION clinical development program who demonstrated a sustained PCSK9 suppression of about 80% and time-adjusted LDL-C reduction of approximately 50% from baseline. Furthermore, the safety profile of inclisiran was found to be comparable to that of mAb PCSK9i and the most commonly reported adverse effect was a mild-to-moderate transient injection site reaction [3]. It provides a therapeutic","PeriodicalId":23021,"journal":{"name":"Therapeutic Apheresis and Dialysis","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10502438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
Therapeutic Apheresis and Dialysis
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1